General personality dimensions are associated with clinical severity and treatment response in individuals with depression and many anxiety disorders, but little is known about these relationships in individuals with obsessive–compulsive disorder (OCD). Individuals in the current study included 705 adults with OCD who had participated in family and genetic studies of the disorder. Participants self‐completed the Neuroticism, Extraversion, Openness Personality Inventory or Neuroticism, Extraversion, Openness Five‐Factor Inventory‐3. Relationships between personality scores, and subjective impairment and OCD treatment response, were evaluated. The odds of subjective impairment increased with (unit increase in) the neuroticism score (odds ratio, OR = 1.03; 95% CI = 1.01–1.04; p < 0.01) and decreased with extraversion scores (OR = 0.98; 95% CI = 0.96–0.99; p < 0.01). The odds of reporting a good response to serotonin/selective serotonin reuptake inhibitors (OR = 1.02; 95% CI = 1.01–1.04; p < 0.01) or cognitive behavioural therapy (OR = 1.03; 95% CI = 1.01–1.05; p < 0.01) increased with the extraversion score. The magnitude of these relationships did not change appreciably after adjusting for other clinical features related to one or more of the personality dimensions. The findings suggest that neuroticism and extraversion are associated with subjective impairment, and that extraversion is associated with self‐reported treatment response, in individuals with OCD. © 2019 John Wiley & Sons, Ltd.

中文翻译：

---

强迫症的一般人格维度、损伤和治疗反应。


一般人格维度与抑郁症和许多焦虑症患者的临床严重程度和治疗反应有关，但人们对强迫症 (OCD) 患者的这些关系知之甚少。当前研究中的个体包括 705 名患有强迫症的成年人，他们参与了该疾病的家庭和遗传研究。参与者自行完成了神经质、外向性、开放性人格量表或神经质、外向性、开放性五因素量表‐3。评估了人格评分、主观损伤和强迫症治疗反应之间的关系。主观损伤的几率随着神经质评分（OR = 1.03；95% CI = 1.01–1.04； p < 0.01）的增加而增加，并随着外向性评分的增加而降低（OR = 0.98；95% CI = 0.96–0.99； p < 0.01)。对血清素/选择性血清素再摄取抑制剂（OR = 1.02；95% CI = 1.01–1.04； p < 0.01）或认知行为疗法（OR = 1.03；95% CI = 1.01–1.05； p < 0.01) 随着外向性得分的增加而增加。在调整与一个或多个人格维度相关的其他临床特征后，这些关系的大小没有明显变化。研究结果表明，对于强迫症患者来说，神经质和外向性与主观损伤有关，外向性与自我报告的治疗反应有关。 © 2019 约翰威利父子公司。